| |
|
|
|
|
|
|
|||
|
Blood, 15 November 2004, Vol. 104, No. 10, pp. 3349-3354. Prepublished online as a Blood First Edition Paper on July 22, 2004; DOI 10.1182/blood-2004-05-1798.
Submitted May 11, 2004
Molecular Cancer Biology Program, Biomedicum Helsinki & Haartman Institute, University of Helsinki, Helsinki, Finland * Corresponding author; email: Paivi.Ojala{at}helsinki.fi.
Primary effusion lymphomas (PELs) represent a unique non-Hodgkin's lymphoma, which is consistently infected by Kaposi's sarcoma herpesvirus (KSHV). PEL cells express high levels of the cell cycle inhibitor p27KIP1 and yet proliferate actively. KSHV genome encodes a viral cyclin homolog, v-cyclin, which has previously been implicated in downregulation of p27KIP1 levels. To address how PEL cells can tolerate high p27KIP1 we investigated functional interactions between v-cyclin and p27KIP1 using PEL derived cell lines as a model system. Here we demonstrate that v-cyclin and p27KIP1 stably associate in PEL cells in vivo suggesting an attractive model by which p27KIP1 is inactivated in the actively proliferating PEL cells. Moreover, we show that v-cyclin and CDK6 form an active kinase without p27KIP1 and that CDK6 is the in vivo catalytic subunit of v-cyclin in PEL cells. These findings suggest that KSHV may promote oncogenesis in PEL by expressing v-cyclin which both overrides negative cell cycle controls present in the PEL precursor cells and induces a strong proliferative signal via CDK6 kinase activity.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||